Erlotinib Treatment for Advanced Lung Cancer in Mexico
Author Information
Author(s): Puerto Víctor Lira, Aldo Castagnari
Primary Institution: Departamento de Oncología Médica, Hospital ABC México
Hypothesis
Can erlotinib be an effective first-line treatment for advanced non-small-cell lung cancer in patients in Mexico?
Conclusion
Erlotinib may be a beneficial first-line treatment option for elderly patients and women with adenocarcinoma.
Supporting Evidence
- Four patients achieved complete remission, and seven showed partial response.
- Female non-smokers had the best therapeutic response to erlotinib treatment.
- Erlotinib could be considered as a first-line therapeutic option for elderly patients.
Takeaway
Doctors gave a medicine called erlotinib to 17 people with lung cancer, and some of them got better, especially women who didn't smoke.
Methodology
The study involved 17 patients treated with erlotinib, with follow-ups to monitor disease progression and response.
Potential Biases
Selection bias due to non-random assignment of patients based on tumor histology and smoking history.
Limitations
The small sample size and non-random selection of patients may limit the generalizability of the results.
Participant Demographics
Median age of participants was 64 years, with 9 females and 11 non-smokers.
Want to read the original?
Access the complete publication on the publisher's website